Johnson & Johnson Starts Late-Stage Coronavirus Vaccine Clinical Trial

Johnson & Johnson (NYSE: JNJ) has moved into phase 3 development of its coronavirus vaccine candidate, which goes by the code name JNJ-78436735. The study, called Ensemble, will enroll up to 60,000 volunteers across three continents.

The company trails Moderna (NASDAQ: MRNA), AstraZeneca (NYSE: AZN), and the duo of Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), which are all in the process of finishing up enrollment in phase 3 clinical trials for their own COVID-19 vaccine candidates. It may also take Johnson & Johnson longer to reach full enrollment in its study given its larger size. Moderna plans to enroll 30,000 people in its trial, while AstraZeneca is shooting for 50,000 across multiple phase 3 studies, and Pfizer and BioNtech recently announced that they had increased their enrollment target from 30,000 to 44,000.

Image source: Getty Images.

Continue reading

Source Fool.com